Track topics on Twitter Track topics that are important to you
Absolute Antibody has announced its mouse knob-into-hole (KIH) bispecific antibody reagents.
Bispecific antibodies, which permit simultaneous engagement of two different protein targets, are a recently developed class of therapeutics, but many of the formats developed for human antibodies do not readily transfer to murine antibodies. Absolute Antibody’s murine bispecific reagents enable researchers and drug developers to more easily evaluate potential bispecific combinations in mouse models.
The company’s bispecific antibodies are fully murine, meaning they can be used in vivo without rapidly inducing neutralising, anti-drug antibodies. In addition, the antibodies can be engineered with a silenced Fc domain when desirable for the biological activity of the bispecific, while still retaining FcRn-mediated recycling capabilities. All antibodies are produced recombinantly for ensured batch-to-batch reproducibility, and offer high purity and low endotoxin levels suitable for in vivo applications.
The mouse bispecific antibodies have been created to target key proteins involved in different immunological pathways, including PD-L1, CD3ε and CD47. Researchers can also build their own custom bispecific reagent, selecting two targets to combine into one antibody reagent. Users can then explore in mouse models how their selected targets might work in combination as a surrogate for a therapeutic bispecific antibody.
Original Article: Absolute Antibody mouse bispecific antibody reagentsNEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...